NVAXNOVAVAX INC

Nasdaq novavax.com


$ 11.98 $ 0.03 (0.25 %)    

Friday, 23-Aug-2024 15:59:58 EDT
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.55 $ -0.64 (-0.11 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 11.99
$ 11.98 x 100
-- x --
-- - --
$ 3.53 - $ 23.86
4,406,188
na
1.92B
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-11-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 03-18-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 03-14-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-08-2017 03-31-2017 10-Q
31 02-27-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-05-2016 03-31-2016 10-Q
35 02-29-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-07-2015 03-31-2015 10-Q
39 02-27-2015 12-31-2014 10-K
40 11-06-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

- Press Conference

 us-fda-official-says-cant-comment-on-novavax-covid-19-vaccine-but-says-the-agency-would-take-rapid-action-once-they-receive-data

- Reuters

 fda-approves-updated-covid-vaccines-from-pfizer-and-moderna-but-leaves-out-novavaxs-shot

The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new...

 novavax-continues-to-work-with-the-us-fda-on-authorization-of-2024-2025-formula-covid-19-vaccine-expect-to-have-authorization-for-2024-2025-formula-covid-19-vaccine-in-time-for-peak-vaccination-season

- Reuters

Core News & Articles

- Reuters 

 fda-set-to-approve-covid-19-vaccines-as-soon-as-this-week-stocks-etfs-to-watch

The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer ou...

 b-riley-securities-reiterates-buy-on-novavax-lowers-price-target-to-23

B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $25 ...

 jp-morgan-maintains-underweight-on-novavax-raises-price-target-to-9

JP Morgan analyst Eric Joseph maintains Novavax (NASDAQ:NVAX) with a Underweight and raises the price target from $8 to $9.

 covid-19-vaccine-maker-novavax-trims-annual-outlook-as-q2-sales-take-a-hit

Novavax reported Q2 2024 revenue of $415 million, missing estimates, with net income rising to $162 million. EPS increased to $...

 novavax-exec-says-updated-covid-vaccine-arriving-in-us-warehouse-this-month-distribution-to-start-after-fda-authorization-expects-more-successful-us-vaccination-season-compared-to-last-year-data-indicates-vaccine-targeting-jn1-should-provide-coverage-for-current-variants

- Conference Call

 novavax-q2-2024-gaap-eps-099-misses-164-estimate-sales-415484m-miss-458575m-estimate

Novavax (NASDAQ:NVAX) reported quarterly earnings of $0.99 per share which missed the analyst consensus estimate of $1.64 by 39...

 b-riley-securities-maintains-buy-on-novavax-lowers-price-target-to-25

B. Riley Securities analyst Mayank Mamtani maintains Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $29 t...

 whats-going-on-with-novavax-nvax-stock

Novavax shares are trading lower by 5.5% Thursday morning. Shares of several vaccine makers are trading lower after Moderna rev...

 jp-morgan-downgrades-novavax-to-underweight-announces-8-price-target

JP Morgan analyst Eric Joseph downgrades Novavax (NASDAQ:NVAX) from Neutral to Underweight and announces $8 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION